Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: Indication of drug pressure

Journal of Infectious Diseases

Volumn 202, Issue 7, 2010, Pages 1088-1094

  Hodel, Eva Maria ^a   Genton, Blaise ^a,b   Zanolari, Boris ^b   Mercier, Thomas ^b   Duong, Socheat ^d   Beck, Hans Peter ^a   Olliaro, Piero ^c   Decosterd, Laurent Arthur ^b   Ariey, Frédéric ^d  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c WORLD BANK   (United States)

^d INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DEBUTYLLUMEFANTRINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DRUG METABOLITE; DUO COTECXIN; ELOQUINE; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE; PYRONARIDINE; QUININE; SULFADOXINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CAMBODIA; CHILD; DRUG BLOOD LEVEL; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRETREATMENT DRUG BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; BLOOD; CHEMISTRY; DRUG RESISTANCE; GENETIC SELECTION; MIDDLE AGED; SERUM;

ADOLESCENT; ADULT; ANTIMALARIALS; CAMBODIA; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; QUININE; QUINOLINES; SELECTION, GENETIC; SERUM; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 77956899495     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655779     Document Type: Article

References (30)

1. Maude R, Pontavornpinyo W, Saralamba S, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009; 8:31.
2. World Health Organization (WHO). The use of antimalarial drugs: report of an informal consultation. Document WHO/CDS/RBM/2001.33. Geneva, Switzerland: WHO, 2000.
3. World Health Organization (WHO). Antimalarial drug combination therapy: report of a WHO technical consultation. Document WHO/ CDS/RBM/2001.35. Geneva, Switzerland: WHO, 2001.
4. World Health Organization (WHO).WHOguidelines for the treatment of malaria. Document WHO/HTM/MAL/2006.1108. Geneva, Switzerland: WHO, 2006.
5. Enserink M. Malaria: signs of drug resistance rattle experts, trigger bold plan. Science 2008; 322:1776.
6. Burki T. Artemisinin resistance could endanger fight against malaria. Lancet Infect Dis 2009; 9:213.
7. Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiol Rec 2007; 82:360.
8. Antimalarial drug resistance, Thai-Cambodian border. Wkly Epidemiol Rec 2009; 84:94-95.
9. World Health Organization (WHO). Drug resistance could set back malaria control success. Geneva, Switzerland: WHO, 2009. http://www.who.int/mediacentre/ news/releases/2009/malaria-drug-resistance-2009 0225/en/index.html. Accessed 10 August 2010.
10. Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-2620.
11. Duffy P, Sibley C. Are we losing artemisinin combination therapy already? Lancet 2005; 366:1908-1909.
12. Dondorp A, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467.
13. Samarasekera U. Countries race to contain resistance to key antimalarial. Lancet 2009; 374:277-280.
14. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg 1986; 89:277-289. (Pubitemid 17230038)
15. Wongsrichanalai C, Meshnick S. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008; 14:716-719. (Pubitemid 351838633)
16. Yeung S, Van Damme W, Socheat D, White N, Mills A. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J 2008; 7:96. (Pubitemid 351990315)
17. ACTwatch - Evidence for Malaria Medicines Policy. ACTwatch in Cambodia. http://www.actwatch.info/results/country-select.asp. Accessed 10 August 2010.
18. Hodel E, Zanolari B, Mercier T, et al. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:867-886.
19. World Health Organization (WHO). Monitoring antimalarial drug resistance: report of a WHO consultation. Document WHO/CDS/RBM/ 2002.39. Geneva, Switzerland: WHO, 2002.
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for industry: bioanalytical method validation. 2001.
21. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Na Bangchang K, Karbwang J, White N. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. Br J Clin Pharmacol 1991; 31:556-559.
22. Karbwang J, Bangchang K, Bunnag D, Harinasuta T. Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. Bull World Health Organ 1991; 69:207-212.
23. Tarning J, Ashley E, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin- piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008; 52:1052-1061.
24. Price R, Simpson J, Teja-Isavatharm P, et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother 1999; 43:341-346.
25. Simpson J, Watkins E, Price R, Aarons L, Kyle D, White N. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 2000; 44:3414-3424. (Pubitemid 33009503)
26. Le Jouan M, Jullien V, Tetanye E, et al. Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum. Antimicrob Agents Chemother 2005; 49:3658-3662.
27. Pukrittayakamee S,Wanwimolruk S, Stepniewska K, et al. Quinine pharmacokinetic- pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 2003; 47:3458-3463.
28. World Health Organization (WHO). Global malaria control and elimination: report of a technical review. Geneva, Switzerland: WHO, 2008. http://malaria.who.int/docs/elimination/MalariaControlElimination Meeting.pdf. Accessed 10 August 2010.
29. Price R, Hasugian A, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 2007; 51:4090-4097.
30. Newton P, van Vugt M, Teja-Isavadharm P, et al. Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother 2002; 46:1125-1127.